CFO Julie Brown’s 2023 GSK (NYSE: GSK) share award vests 82%

Rhea-AI Filing Summary

GSK plc reports the vesting of a 2023 Performance Share Plan award granted to its Chief Financial Officer, Julie Brown. Following performance assessment, 82% of this award vested and 18% lapsed.

The vesting delivered 243,880 Ordinary Shares at a price of £0.00 per share, including dividend equivalents, on 27 April 2026. These vested shares are subject to an additional two-year holding period. The closing price of GSK Ordinary Shares on the vesting date was £20.16.

Key Figures

PSP shares vested: 243,880 shares Vesting price per share: £0.00 per share Share closing price: £20.16 +4 more

7 metrics

PSP shares vested 243,880 shares 2023 Performance Share Plan award for CFO vested on 27 April 2026

Vesting price per share £0.00 per share Delivery price for vested PSP shares to CFO

Share closing price £20.16 Closing price of GSK Ordinary Shares on 27 April 2026

Vesting proportion 82% Portion of CFO’s 2023 PSP award that vested

Lapsed proportion 18% Portion of CFO’s 2023 PSP award that lapsed

Holding period Two years Additional holding period on CFO’s vested PSP shares

Transaction date 27 April 2026 Date of PSP award vesting for CFO Julie Brown

Key Terms

Performance Share Plan, PDMR, holding period, conditional share award

4 terms

Performance Share Plan financial

"a conditional share award made under the GSK 2017 Performance Share Plan ('PSP')"

A performance share plan grants company shares to employees or executives only if the business meets specific targets over a set period, so the reward depends on results rather than being automatic. For investors it matters because it aligns managers’ pay with company performance—like promising a team stock instead of cash if they hit goals—which can influence future share count, shareholder value, and how confidently management pursues growth.

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

holding period financial

"For the CFO, the vested shares are subject to an additional two-year holding period."

conditional share award financial

"the vesting details of a conditional share award made under the GSK 2017 Performance Share Plan"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Vesting of 2023 Performance Share Plan Award

This notification sets out the vesting details of a conditional share award made under the GSK 2017 Performance Share Plan ('PSP') to the Chief Financial Officer (CFO) on 27 April 2023 upon her joining GSK as CFO Designate.

Following the third anniversary of the grant, this 2023 PSP award has now vested on the same basis as the 2023 PSP awards which vested on 13 February 2026, with 82% vesting and 18% lapsed. Details of the performance measure outcomes and vesting levels are set out in the announcement of 17 February 2026.

For the CFO, the vested shares are subject to an additional two-year holding period.  

The notification that follows details the number of shares that vested under this 2023 PSP award for the CFO, including dividends accrued, on 27 April 2026. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £20.16.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of awards granted in 2023 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	243,880
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-27
f)	Place of the transaction	N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: April 28, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) disclose in this April 2026 Form 6-K?

GSK disclosed that a 2023 Performance Share Plan award granted to CFO Julie Brown vested. 82% of the award vested and 18% lapsed, resulting in 243,880 Ordinary Shares being delivered at £0.00 per share, including accrued dividends, on 27 April 2026.

How many GSK (GSK) shares vested for the CFO under the 2023 PSP award?

The CFO, Julie Brown, received 243,880 GSK Ordinary Shares when her 2023 Performance Share Plan award vested. These shares, including dividend equivalents, were delivered at £0.00 per share on 27 April 2026 as part of her long-term incentive compensation.

What portion of GSK (GSK) CFO’s 2023 Performance Share Plan award lapsed?

GSK states that 82% of the CFO’s 2023 Performance Share Plan award vested and 18% lapsed. The vesting outcome followed the same basis as other 2023 PSP awards that vested in February 2026, reflecting assessed performance against pre-set measures.

Is there a holding period on the vested GSK (GSK) shares for the CFO?

Yes. The vested shares for GSK’s CFO are subject to an additional two-year holding period. This means Julie Brown must retain the 243,880 vested Ordinary Shares for two years after vesting, aligning her interests with longer-term shareholder outcomes.

What was GSK (GSK) share price on the PSP vesting date for the CFO?

On the vesting date of 27 April 2026, GSK’s Ordinary Shares closed at £20.16. Although the CFO received 243,880 shares at £0.00 per share under the Performance Share Plan, this closing price indicates the market value of the shares on that day.